Sign up for our newsletter
All-time Popular Posts
A biobetter trastuzumab is on the way
EGA president calls on Member States to boost market access for biosimilars in the EU
3rd Forum on Biosimilars
Pfizer starts biosimilar rituximab Phase I/II trial
Indian Biosimilars Market
World’s first biosimilar antibody* is approved in Korea
A biosimilar manufacturer: Celltrion
GPhA applauds Senate HELP Committee for favorably reporting user fee proposals
Tags
Amgen BPCIA Celltrion Conference EMA Enbrel EU FDA Genentech Guideline Herceptin Hospira India infliximab Interchangeability Japan London Mabthera Market Research Monoclonal Antibodies Press Release Remicade Rituxan rituximab Roche Sandoz South Korea Teva Training trastuzumab UK USAArchives
Post Tagged with: "Guidance"
Recent Comments
- VITHALRAO KULKARNI on Indian Biosimilars Market
- VITHALRAO KULKARNI on Nippon Kayaku announces marketing approval of infliximab biosimilar in Japan
- Biosimilar News on Indian Biosimilars Market
- Yamak Mehta
Twitter: ymk108
on Indian Biosimilars Market - Habib Zalila on 4th Annual Biopharmaceuticals Meeting
Share an Article?
Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.
We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?
Suggestions?
Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!